by Columbia University Irving Medical Center Credit: Pixabay/CC0 Public Domain Brain metastasis is one of the most common causes of cancer-related deaths and occurs very frequently in patients with advanced melanoma. Although new immunotherapies are effective in some patients with melanoma brain metastases, little is known about the reasons for melanoma’s spread to the brain...
by Dana-Farber Cancer Institute A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need. The drug, cabozantinib, is a tyrosine kinase inhibitor that attacks several targets in cancer cells....
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS Phase III clinical trial results reported today in the New England Journal of Medicine and presented concurrently at the San Antonio Breast Cancer Symposium (SABCS) 2019 show the combination of the investigational drug tucatinib with standard of care treatment including the drugs trastuzumab and capecitabine nearly tripled one-year progression-free survival (33...
